Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Abacavir, dolutegravir, lamivudine

(Triumeq®)

Triumeq®

Drug updated on 12/11/2024

Dosage FormTablet (oral; 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine); PD Tablet (oral; 60 mg of abacavir, 5 mg of dolutegravir, and 30 mg of lamivudine)
Drug ClassIntegrase strand transfer inhibitors [INSTI] and nucleoside analogue reverse transcriptase inhibitors [NRTI]
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 10 kg.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • The rate of virologic suppression (human immunodeficiency virus (HIV)-1 RNA < 50 copies/mL) and virologic failure (HIV-1 RNA ≥ 50 copies/mL) at Week 144 was similar across the dolutegravir (DTG) + lamivudine (3TC), bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), and DTG/abacavir/3TC (DTG/ABC/3TC) regimens.
  • In genital fluid HIV detection, 87% of participants on dual therapy (tenofovir/emtricitabine) and 93% on triple therapy had no detectable HIV in the TRULIGHT trial, while 80% on monotherapy (dolutegravir) and 81% on triple therapy showed no detectable HIV in the dolutegravir (MONCAY trial); pooled analysis indicated 83% with no detectable HIV in lower drug regimens versus 87% in triple therapy.
  • There were no significant differences in mean changes in CD4+ cell count at Week 144 across DTG + 3TC, BIC/FTC/TAF, and DTG/ABC/3TC.
  • Serious adverse events were significantly less frequent with DTG + 3TC compared to BIC/FTC/TAF (odd ratio (OR), 0.51; 95% confidence interval (CI) 0.29-0.87; P = 0.014) and DTG/ABC/3TC (OR, 0.38; 95% CI 0.19-0.75; P = 0.006); discontinuations and overall adverse events were similar across all regimens.
  • There were no specific safety outcomes or adverse effects reported in relation to lower drug regimens (LDRs) versus triple therapies.
  • There is no population type or subgroup information available in the reviewed studies.